LIVIVO - Search results -

Search results

Result 1 - 10 of total 49

Search options

Article ; Online: An mHealth application for chronic vascular access: A multi-method evaluation.

Ullman, Amanda J / Larsen, Emily / Gibson, Victoria / Binnewies, Sebastian / Ohira, Ryoma / Marsh, Nicole / Mcbride, Craig / Winterbourn, Karen / Boyte, Francesca / Cunninghame, Jacqueline / Dufficy, Mitchell / Plummer, Karin / Roberts, Natasha / Takashima, Mari / Cooke, Marie / Byrnes, Joshua / Rickard, Claire M / Kleidon, Tricia M

Journal of clinical nursing

2024 Volume 33, Issue 5, Page(s) 1762–1776

Abstract: Background: Healthcare consumers require diverse resources to assist their navigation of complex healthcare interactions, however, these resources need to be fit for purpose.: Aim: In this study, we evaluated the utility, usability and feasibility of ...

Abstract	Background: Healthcare consumers require diverse resources to assist their navigation of complex healthcare interactions, however, these resources need to be fit for purpose. Aim: In this study, we evaluated the utility, usability and feasibility of children, families and adults requiring long-term intravenous therapy using a recently developed mobile health application (App), intravenous (IV) Passport. Design: Multi-site, parallel, multi-method, prospective cohort study. Methods: A multi-site, multi-method study was carried out in 2020-2021, with 46 participants (20 adults, 26 children/family) reporting on their experiences surrounding the use of the IV Passport for up to 6 months. Results: Overall, utility rates were acceptable, with 78.3% (N = 36) using the IV Passport over the follow-up period, with high rates of planned future use for those still active in the project (N = 21; 73%), especially in the child/family cohort (N = 13; 100%). Acceptability rates were high (9/10; IQR 6.5-10), with the IV Passport primarily used for documenting new devices and complications. Thematic analysis revealed three main themes (and multiple subthemes) in the qualitative data: Advocacy for healthcare needs, Complexity of healthcare and App design and functionality. Conclusion: Several recommendations were made to improve the end-user experience including 'how to' instructions; and scheduling functionality for routine care. Implications for the profession and/or patient care: The IV Passport can be safely and appropriately integrated into healthcare, to support consumers. Impact: Patient-/parent-reported feedback suggests the Intravenous Passport is a useful tool for record-keeping, and positive communication between patients/parents, and clinicians. Reporting method: Not applicable. Patient contribution: Consumers reported their experiences surrounding the use of the IV Passport for up to 6 months.
MeSH term(s)	Adult ; Child ; Humans ; Prospective Studies ; Telemedicine/methods ; Delivery of Health Care ; Parents ; Communication
Language	English
Publishing date	2024-02-27
Publishing country	England
Document type	Journal Article
ZDB-ID	1159483-4
ISSN	1365-2702 ; 0962-1067 ; 1752-9816
ISSN (online)	1365-2702
ISSN	0962-1067 ; 1752-9816
DOI	10.1111/jocn.17034
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3764: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early pregnancy cardio metabolic risk factors and the prevalence of metabolic syndrome 10 years after the first pregnancy.

Andraweera, Prabha H / Plummer, Michelle D / Garrett, Amy / Leemaqz, Shalem / Wittwer, Melanie R / Aldridge, Emily / Pathirana, Maleesa M / Dekker, Gus A / Roberts, Claire T / Arstall, Margaret A

PloS one

2023 Volume 18, Issue 1, Page(s) e0280451

Abstract: Background: We aimed to compare risk factors for CVD 10 years postpartum among women who had ≥ 1 compared to no cardio metabolic risk factor in early first pregnancy.: Methods: Women of the SCOPE (Screening fOr Pregnancy Endpoints) study from ... ...

Abstract	Background: We aimed to compare risk factors for CVD 10 years postpartum among women who had ≥ 1 compared to no cardio metabolic risk factor in early first pregnancy. Methods: Women of the SCOPE (Screening fOr Pregnancy Endpoints) study from Adelaide, South Australia were invited to participate in a cardiovascular risk assessment 10 years after the delivery of the first child. Data from 141 women who completed all the assessments are included in the analyses. Result: Compared to women who did not have any cardio metabolic risk factor at 15 ± 1 weeks' gestation during the first pregnancy, those who had ≥ 1 risk factor were 5.5 times more likely to have metabolic syndrome 10 years postpartum (aOR = 5.5, 95% CI 1.8-17.3, p = 0.004). Women who had ≥ 1cardio metabolic risk factor during the first pregnancy were more likely to be obese (p = 0.001), have high total cholesterol levels (p <0.001) or have increased insulin resistance (p <0.001) 10 years later compared to women who had no risk factor during the first pregnancy. 63.5% of the women with no cardio metabolic risk factor compared to 39% of women who had ≥ 1 risk factor in first pregnancy, had neither a complicated first pregnancy nor was diagnosed with MetS 10 years postpartum (p = 0.023). Conclusion: Cardio metabolic risk factors at the booking visit in the first pregnancy may be useful in identifying young women at risk of future CVD.
MeSH term(s)	Female ; Humans ; Pregnancy ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Metabolic Syndrome/complications ; Obesity/epidemiology ; Pregnancy Complications/epidemiology ; Prevalence ; Risk Factors
Language	English
Publishing date	2023-01-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0280451
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Mouse models for dengue vaccines and antivirals.

Plummer, Emily M / Shresta, Sujan

Journal of immunological methods

2014 Volume 410, Page(s) 34–38

Abstract: Dengue virus (DENV) has substantial global impact, with an estimated 390million people infected each year. In spite of this, there is currently no approved DENV-specific vaccine or antiviral. One reason for this is the difficulty involved with ... ...

Abstract	Dengue virus (DENV) has substantial global impact, with an estimated 390million people infected each year. In spite of this, there is currently no approved DENV-specific vaccine or antiviral. One reason for this is the difficulty involved with development of an adequate animal model. While non-human primates support viral replication, they do not exhibit signs of clinical disease. A mouse model is an ideal alternative; however, wild-type mice are resistant to DENV-induced disease. Infection of interferon receptor-deficient mice results in disease that recapitulates key features of severe dengue disease in humans. For the development of vaccines, interferon receptor-deficient mice provide a stringent model for testing vaccine-induced immune components from vaccinated wild-type mice.
MeSH term(s)	Animals ; Dengue/genetics ; Dengue/immunology ; Dengue/prevention & control ; Dengue Vaccines/genetics ; Dengue Vaccines/immunology ; Dengue Virus/physiology ; Disease Models, Animal ; Humans ; Interferon-gamma/genetics ; Interferon-gamma/immunology ; Mice ; Mice, Mutant Strains ; Virus Replication/genetics ; Virus Replication/immunology
Chemical Substances	Dengue Vaccines ; Interferon-gamma (82115-62-6)
Language	English
Publishing date	2014-08
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	120142-6
ISSN	1872-7905 ; 0022-1759
ISSN (online)	1872-7905
ISSN	0022-1759
DOI	10.1016/j.jim.2014.01.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 795: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Mouse models for dengue vaccines and antivirals

Plummer, Emily M / Sujan Shresta

Journal of Immunological Methods. 2014 Aug., v. 410

2014

Abstract	Dengue virus (DENV) has substantial global impact, with an estimated 390million people infected each year. In spite of this, there is currently no approved DENV-specific vaccine or antiviral. One reason for this is the difficulty involved with development of an adequate animal model. While non-human primates support viral replication, they do not exhibit signs of clinical disease. A mouse model is an ideal alternative; however, wild-type mice are resistant to DENV-induced disease. Infection of interferon receptor-deficient mice results in disease that recapitulates key features of severe dengue disease in humans. For the development of vaccines, interferon receptor-deficient mice provide a stringent model for testing vaccine-induced immune components from vaccinated wild-type mice.
Keywords	animal models ; antiviral agents ; dengue ; Dengue virus ; humans ; interferons ; mice ; people ; Primates ; vaccine development ; vaccines ; virus replication
Language	English
Dates of publication	2014-08
Size	p. 34-38.
Publishing place	Elsevier B.V.
Document type	Article
ZDB-ID	120142-6
ISSN	1872-7905 ; 0022-1759
ISSN (online)	1872-7905
ISSN	0022-1759
DOI	10.1016/j.jim.2014.01.001
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.A 795: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Endocytic uptake pathways utilized by CPMV nanoparticles.

Plummer, Emily M / Manchester, Marianne

Molecular pharmaceutics

2012 Volume 10, Issue 1, Page(s) 26–32

Abstract: Cowpea mosaic virus (CPMV) has been used as a nanoparticle platform for biomedical applications including vaccine development, in vivo vascular imaging, and tissue-targeted delivery. A better understanding of the mechanisms of CPMV targeting and cell ... ...

Abstract	Cowpea mosaic virus (CPMV) has been used as a nanoparticle platform for biomedical applications including vaccine development, in vivo vascular imaging, and tissue-targeted delivery. A better understanding of the mechanisms of CPMV targeting and cell internalization would enable enhanced targeting and more effective delivery. Previous studies showed that, following binding and internalization by mammalian cells, CPMV localizes in a perinuclear late-endosome compartment where it remains for as long as several days. To further investigate endocytic trafficking of CPMV within the cell, we used multiple approaches including pharmacologic inhibition of pathways and colocalization with endocytic vesicle compartments. CPMV internalization was clathrin-independent and utilized a combination of caveolar endocytosis and macropinocytosis pathways for entry. CPMV particles colocalized with Rab5(+) early endosomes to traffic ultimately to a lysosomal compartment. These studies facilitate the further development of effective intracellular drug-delivery strategies using CPMV.
MeSH term(s)	Animals ; Biological Transport ; Cells, Cultured ; Comovirus/metabolism ; Drug Delivery Systems/methods ; Endocytosis/physiology ; Endosomes/metabolism ; Endosomes/physiology ; Endosomes/virology ; HeLa Cells ; Humans ; Macrophages/metabolism ; Macrophages/virology ; Mice ; Nanoparticles/administration & dosage ; Pinocytosis/physiology
Language	English
Publishing date	2012-09-20
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2138405-8
ISSN	1543-8392 ; 1543-8384
ISSN (online)	1543-8392
ISSN	1543-8384
DOI	10.1021/mp300238w
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6250: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.

Plummer, Emily M / Manchester, Marianne

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

2010 Volume 3, Issue 2, Page(s) 174–196

Abstract: Current vaccines that provide protection against infectious diseases have primarily relied on attenuated or inactivated pathogens. Virus-like particles (VLPs), comprised of capsid proteins that can initiate an immune response but do not include the ... ...

Abstract	Current vaccines that provide protection against infectious diseases have primarily relied on attenuated or inactivated pathogens. Virus-like particles (VLPs), comprised of capsid proteins that can initiate an immune response but do not include the genetic material required for replication, promote immunogenicity and have been developed and approved as vaccines in some cases. In addition, many of these VLPs can be used as molecular platforms for genetic fusion or chemical attachment of heterologous antigenic epitopes. This approach has been shown to provide protective immunity against the foreign epitopes in many cases. A variety of VLPs and virus-based nanoparticles are being developed for use as vaccines and epitope platforms. These particles have the potential to increase efficacy of current vaccines as well as treat diseases for which no effective vaccines are available.
MeSH term(s)	Animals ; Humans ; Nanomedicine/methods ; Nanoparticles/chemistry ; Viral Vaccines/chemistry ; Viral Vaccines/immunology ; Virion/chemistry ; Virion/immunology ; Viruses/chemistry ; Viruses/immunology
Chemical Substances	Viral Vaccines
Keywords	covid19
Language	English
Publishing date	2010-09-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2502698-7
ISSN	1939-0041 ; 1939-5116
ISSN (online)	1939-0041
ISSN	1939-5116
DOI	10.1002/wnan.119
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6781: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Expanded geographic distribution and dietary strategies of the earliest Oldowan hominins and

Plummer, Thomas W / Oliver, James S / Finestone, Emma M / Ditchfield, Peter W / Bishop, Laura C / Blumenthal, Scott A / Lemorini, Cristina / Caricola, Isabella / Bailey, Shara E / Herries, Andy I R / Parkinson, Jennifer A / Whitfield, Elizabeth / Hertel, Fritz / Kinyanjui, Rahab N / Vincent, Thomas H / Li, Youjuan / Louys, Julien / Frost, Stephen R / Braun, David R /

Reeves, Jonathan S / Early, Emily D G / Onyango, Blasto / Lamela-Lopez, Raquel / Forrest, Frances L / He, Huaiyu / Lane, Timothy P / Frouin, Marine / Nomade, Sébastien / Wilson, Evan P / Bartilol, Simion K / Rotich, Nelson Kiprono / Potts, Richard

Science (New York, N.Y.)

2023 Volume 379, Issue 6632, Page(s) 561–566

Abstract: The oldest Oldowan tool sites, from around 2.6 million years ago, have previously been confined to Ethiopia's Afar Triangle. We describe sites at Nyayanga, Kenya, dated to 3.032 to 2.581 million years ago and expand this distribution by over 1300 ... ...

Abstract	The oldest Oldowan tool sites, from around 2.6 million years ago, have previously been confined to Ethiopia's Afar Triangle. We describe sites at Nyayanga, Kenya, dated to 3.032 to 2.581 million years ago and expand this distribution by over 1300 kilometers. Furthermore, we found two hippopotamid butchery sites associated with mosaic vegetation and a C
MeSH term(s)	Animals ; Biological Evolution ; Bone and Bones ; Diet ; Feeding Behavior ; Fossils ; Hominidae ; Kenya ; Plants ; Paleontology
Language	English
Publishing date	2023-02-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	128410-1
ISSN	1095-9203 ; 0036-8075
ISSN (online)	1095-9203
ISSN	0036-8075
DOI	10.1126/science.abo7452
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 27: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 77: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: High-resolution crystal structure and chemical screening reveal pantothenate kinase as a new target for antifungal development.

Gihaz, Shalev / Gareiss, Peter / Choi, Jae-Yeon / Renard, Isaline / Pal, Anasuya Chattopadhyay / Surovsteva, Yulia / Chiu, Joy E / Thekkiniath, Jose / Plummer, Mark / Hungerford, William / Montgomery, Micaela L / Hosford, Alanah / Adams, Emily M / Lightfoot, Jorge D / Fox, David / Ojo, Kayode K / Staker, Bart L / Fuller, Kevin / Ben Mamoun, Choukri

Structure (London, England : 1993)

2022 Volume 30, Issue 11, Page(s) 1494–1507.e6

Abstract: Fungal infections are the leading cause of mortality by eukaryotic pathogens, with an estimated 150 million severe life-threatening cases and 1.7 million deaths reported annually. The rapid emergence of multidrug-resistant fungal isolates highlights the ... ...

Abstract	Fungal infections are the leading cause of mortality by eukaryotic pathogens, with an estimated 150 million severe life-threatening cases and 1.7 million deaths reported annually. The rapid emergence of multidrug-resistant fungal isolates highlights the urgent need for new drugs with new mechanisms of action. In fungi, pantothenate phosphorylation, catalyzed by PanK enzyme, is the first step in the utilization of pantothenic acid and coenzyme A biosynthesis. In all fungi sequenced so far, this enzyme is encoded by a single PanK gene. Here, we report the crystal structure of a fungal PanK alone as well as with high-affinity inhibitors from a single chemotype identified through a high-throughput chemical screen. Structural, biochemical, and functional analyses revealed mechanisms governing substrate and ligand binding, dimerization, and catalysis and helped identify new compounds that inhibit the growth of several Candida species. The data validate PanK as a promising target for antifungal drug development.
MeSH term(s)	Antifungal Agents/pharmacology ; Phosphotransferases (Alcohol Group Acceptor)/genetics ; Phosphotransferases (Alcohol Group Acceptor)/metabolism ; Pantothenic Acid/chemistry ; Pantothenic Acid/metabolism ; Fungi
Chemical Substances	Antifungal Agents ; pantothenate kinase (EC 2.7.1.33) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; Pantothenic Acid (19F5HK2737)
Language	English
Publishing date	2022-09-26
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	1213087-4
ISSN	1878-4186 ; 0969-2126
ISSN (online)	1878-4186
ISSN	0969-2126
DOI	10.1016/j.str.2022.09.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4141: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.

Papazyan, Romeo / Liu, Xueqing / Liu, Jingwen / Dong, Bin / Plummer, Emily M / Lewis, Ronald D / Roth, Jonathan D / Young, Mark A

Journal of lipid research

2018 Volume 59, Issue 6, Page(s) 982–993

Abstract: Obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist that regulates bile acid and lipid metabolism. FXR activation induces distinct changes in circulating cholesterol among animal models and humans. The mechanistic basis of these ... ...

Abstract	Obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist that regulates bile acid and lipid metabolism. FXR activation induces distinct changes in circulating cholesterol among animal models and humans. The mechanistic basis of these effects has been elusive because of difficulties in studying lipoprotein homeostasis in mice, which predominantly package circulating cholesterol in HDLs. Here, we tested the effects of OCA in chimeric mice whose livers are mostly composed (≥80%) of human hepatocytes. Chimeric mice exhibited a human-like ratio of serum LDL cholesterol (LDL-C) to HDL cholesterol (HDL-C) at baseline. OCA treatment in chimeric mice increased circulating LDL-C and decreased circulating HDL-C levels, demonstrating that these mice closely model the cholesterol effects of FXR activation in humans. Mechanistically, OCA treatment increased hepatic cholesterol in chimeric mice but not in control mice. This increase correlated with decreased SREBP-2 activity and target gene expression, including a significant reduction in LDL receptor protein. Cotreatment with atorvastatin reduced total cholesterol, rescued LDL receptor protein levels, and normalized serum LDL-C. Treatment with two clinically relevant nonsteroidal FXR agonists elicited similar lipoprotein and hepatic changes in chimeric mice, suggesting that the increase in circulating LDL-C is a class effect of FXR activation.
MeSH term(s)	Animals ; Atorvastatin/pharmacology ; Chenodeoxycholic Acid/analogs & derivatives ; Chenodeoxycholic Acid/pharmacology ; Chimera ; Cholesterol/blood ; Cholesterol/metabolism ; Humans ; Lipoproteins/blood ; Lipoproteins/metabolism ; Liver/cytology ; Liver/drug effects ; Liver/metabolism ; Male ; Mice ; Receptors, Cytoplasmic and Nuclear/metabolism
Chemical Substances	Lipoproteins ; Receptors, Cytoplasmic and Nuclear ; lipoprotein cholesterol ; obeticholic acid (0462Z4S4OZ) ; farnesoid X-activated receptor (0C5V0MRU6P) ; Chenodeoxycholic Acid (0GEI24LG0J) ; Cholesterol (97C5T2UQ7J) ; Atorvastatin (A0JWA85V8F)
Language	English
Publishing date	2018-03-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	80154-9
ISSN	1539-7262 ; 0022-2275
ISSN (online)	1539-7262
ISSN	0022-2275
DOI	10.1194/jlr.M081935
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 175: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.

Mwesigwa, Betty / Houser, Katherine V / Hofstetter, Amelia R / Ortega-Villa, Ana M / Naluyima, Prossy / Kiweewa, Francis / Nakabuye, Immaculate / Yamshchikov, Galina V / Andrews, Charla / O'Callahan, Mark / Strom, Larisa / Schech, Steven / Anne Eller, Leigh / Sondergaard, Erica L / Scott, Paul T / Amare, Mihret F / Modjarrad, Kayvon / Wamala, Amir / Tindikahwa, Allan /

Musingye, Ezra / Nanyondo, Jauhara / Gaudinski, Martin R / Gordon, Ingelise J / Holman, LaSonji A / Saunders, Jamie G / Costner, Pamela J M / Mendoza, Floreliz H / Happe, Myra / Morgan, Patricia / Plummer, Sarah H / Hickman, Somia P / Vazquez, Sandra / Murray, Tamar / Cordon, Jamilet / Dulan, Caitlyn N M / Hunegnaw, Ruth / Basappa, Manjula / Padilla, Marcelino / Gajjala, Suprabhath R / Swanson, Phillip A / Lin, Bob C / Coates, Emily E / Gall, Jason G / McDermott, Adrian B / Koup, Richard A / Mascola, John R / Ploquin, Aurélie / Sullivan, Nancy J / Kibuuka, Hannah / Ake, Julie A / Ledgerwood, Julie E

The Lancet. Infectious diseases

2023 Volume 23, Issue 12, Page(s) 1408–1417

Abstract: Background: Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among 164 confirmed cases in the second half of 2022. Although vaccines and ... ...

Abstract	Background: Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among 164 confirmed cases in the second half of 2022. Although vaccines and therapeutics specific for Zaire Ebola virus have been approved for use during outbreak situations, Sudan Ebola virus is an antigenically distinct virus with no approved vaccines available. Methods: In this phase 1, open-label, dose-escalation trial we evaluated the safety, tolerability, and immunogenicity of a monovalent chimpanzee adenovirus 3 vaccine against Sudan Ebola virus (cAd3-EBO S) at Makerere University Walter Reed Project in Kampala, Uganda. Study participants were recruited from the Kampala metropolitan area using International Review Board-approved written and electronic media explaining the trial intervention. Healthy adults without previous receipt of Ebola, Marburg, or cAd3 vectored-vaccines were enrolled to receive cAd3-EBO S at either 1 × 10 Findings: 40 healthy adults were enrolled between July 22 and Oct 1, 2019, with 20 receiving 1 × 10 Interpretation: The cAd3-EBO S vaccine was safe at both doses, rapidly inducing immune responses in most participants after a single injection. The rapid onset and durability of the vaccine-induced antibodies make this vaccine a strong candidate for emergency deployment in Sudan Ebola virus outbreaks. Funding: National Institutes of Health via interagency agreement with Walter Reed Army Institute of Research.
MeSH term(s)	Animals ; Humans ; Adult ; Hemorrhagic Fever, Ebola/prevention & control ; Ebola Vaccines ; Pan troglodytes ; Uganda ; Sudan ; Ebolavirus/genetics ; Antibodies, Viral ; Adenoviruses, Simian/genetics ; Adenoviridae/genetics ; Glycoproteins ; Immunogenicity, Vaccine ; Double-Blind Method
Chemical Substances	Ebola Vaccines ; Antibodies, Viral ; Glycoproteins
Language	English
Publishing date	2023-08-03
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article
ZDB-ID	2061641-7
ISSN	1474-4457 ; 1473-3099
ISSN (online)	1474-4457
ISSN	1473-3099
DOI	10.1016/S1473-3099(23)00344-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5743: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito